MetaCap

PDS Biotechnology Corporation (PDSB)

NASDAQ: PDSBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.7774-0.0299 (-3.70%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PDSB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.39M
EPS (TTM)
-$0.54
52-week range
0.195 – 1.79
Day range
0.7703 – 0.8451
Volume / Avg
2.89M / 25.64M
Beta
—

52-week range

$0.195$1.79

PDSB stock today

Shares of PDS Biotechnology (PDSB) finished lower on Nov 20 at $0.7774, a drop of 3.70% or $0.0299 per share, versus the S&P 500's 3.70% decline. Trading was light, with 2.89M shares changing hands, about 11% of the average daily volume. Shares are 56.6% below their 52-week high of $1.79, set on Oct 13, 2026 and 298.7% above the 52-week low of $0.195, in the middle of the past year's range.

PDSB is up 1.0% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 3.0%. PDS Biotechnology has posted a net loss over the last twelve months (EPS of -$0.54), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About PDS Biotechnology

Company profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein for treating acute myeloid leukemia, prostate, and breast cancer; and PDS0103 for ovarian, breast, colorectal, and lung cancers.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Frank K. Bedu-Addo Ph.D.
Headquarters
Princeton, NJ
Employees
21
IPO year
2015

Financial highlights

Full financials

PDS Biotechnology reported a net loss of $34.5 million, compared with a loss of $37.6 million a year earlier. Diluted earnings per share came in at -$0.74.

PDS Biotechnology annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-34.50M$-37.61M$-42.94M$-40.85M$-16.92M
EPS (diluted)$-0.74$-1.03$-1.39$-1.43$-0.66

Analyst forecast

Forecast

Consensus (2 analysts)

strong_buy

Avg. price target

$4.50+478.85%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $5.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 13, 2026
EPS actual vs est.
$-0.11 vs $-0.09
Surprise
-22.22%

PDSB news

All PDSB news

PDS Biotechnology peers

Health Care sector
PDSB peer companies
CompanyPrice% ChgMarket capCompare
NRXPNRX Pharmaceuticals Inc.2.15-15.69%$95.31Mvs PDSB
NBPNovaBridge Biosciences ADR0.83-5.66%$96.28Mvs PDSB
DERMJourney Medical Corporation3.30-7.04%$93.16Mvs PDSB
UNCYUnicycive Therapeutics Inc.3.35-5.10%$97.77Mvs PDSB
CLLSCellectis S.A. ADR0.9209-7.89%$92.76Mvs PDSB
CNTNCanton Strategic Holdings Inc.1.21-1.63%$98.78Mvs PDSB
NERVMinerva Neurosciences Inc2.00-5.66%$99.67Mvs PDSB
CATXPerspective Therapeutics Inc.0.7538-3.85%$91.03Mvs PDSB

Indexes, lists and sector

PDS Biotechnology stock FAQ

What is PDS Biotechnology's stock price today?

PDSB last traded at $0.7774 as of Nov 20, 4:00 PM EST, down 3.70% on the day. Prices are delayed at least 15 minutes.

Does PDS Biotechnology pay a dividend?

No. PDS Biotechnology does not currently pay a regular cash dividend.

Who is PDS Biotechnology's CEO?

Dr. Frank K. Bedu-Addo Ph.D. is the chief executive officer of PDS Biotechnology Corporation, which has about 21 employees.

Has PDSB ever split its stock?

Yes. The most recent PDSB stock split was a 1-for-20 split on Mar 18, 2019.

What is the PDSB 52-week high?

The 52-week high for PDSB is $1.79 and the 52-week low is $0.195. The stock is currently 56.6% below its high.

Compare PDSB